Healthcare PharmaceuticalsGroundbreaking HER2-targeted biologic cancer therapy (trastuzumab) developed by Genentech and owned by Roche, FDA approved September 25, 1998, that transformed the treatment of HER2-positive breast cancer and now faces biosimilar competition from multiple approved alternatives.
oncologybreast-cancerher2